Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M170Revenue $M0.2Net Margin (%)0Z-Score3.3
Enterprise Value $M89.5EPS $-0.6Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book1.110-y EBITDA Growth Rate %0Quick Ratio17.4Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-24.6Current Ratio17.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-34.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-37.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M70.8ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ONTY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTYJean-Marie Eveillard 2014-09-30 Sold Out -0.02%$2 - $3.29
($2.54)
$ 1.86-27%Sold Out0
ONTYGeorge Soros 2014-06-30 Sold Out $2.35 - $3.5
($2.94)
$ 1.86-37%Sold Out0
ONTYGeorge Soros 2014-03-31 Buy $1.71 - $3.89
($2.7)
$ 1.86-31%New holding, 89600 sh.89,600
ONTYJean-Marie Eveillard 2013-09-30 Add0.01%$1.59 - $2.18
($1.75)
$ 1.866%Add 75.63%2,275,287
ONTYJean-Marie Eveillard 2013-06-30 Add0.01%$1.57 - $2.63
($2.14)
$ 1.86-13%Add 547.75%1,295,499
ONTYAndreas Halvorsen 2013-06-30 Sold Out -0.05%$1.57 - $2.63
($2.14)
$ 1.86-13%Sold Out0
ONTYJean-Marie Eveillard 2013-03-31 Buy $1.86 - $2.35
($2.09)
$ 1.86-11%New holding, 200000 sh.200,000
ONTYJean-Marie Eveillard 2012-03-31 Sold Out -0.0033%$4.16 - $8.96
($6.31)
$ 1.86-70%Sold Out0
ONTYJean-Marie Eveillard 2011-12-31 Add$5.84 - $8.25
($6.85)
$ 1.86-73%Add 33.33%100,000
ONTYAndreas Halvorsen 2011-09-30 Buy 0.22%$5.95 - $10.2
($7.49)
$ 1.86-75%New holding, 3110650 sh.3,110,650
ONTYJean-Marie Eveillard 2011-09-30 Reduce-0.01%$5.95 - $10.2
($7.49)
$ 1.86-75%Reduce -66.67%75,000
ONTYJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.8 - $9.43
($5.79)
$ 1.86-68%New holding, 225000 sh.225,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ONTY Jean-Marie Eveillard 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ONTY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Venkatesan JayEVP and General Manager 2014-09-23Buy250,000$2-7view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy129,000$1.784.49view
BVF PARTNERS L P/IL10% Owner 2013-08-08Buy258,361$1.6512.73view
BVF PARTNERS L P/IL10% Owner 2013-08-01Buy338,087$1.746.9view
SPIEGELMAN DANIEL KDirector 2013-07-10Sell16,183$1.91-2.62view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy214,467$1.812.76view
Ayer Capital Management, LP10% Owner 2011-06-23Sell28,900$8.74-78.72view
Karan Shashi K.Corporate Controller 2010-09-28Buy5,100$3.41-45.45view
Karan Shashi K.Corporate Controller 2009-08-18Buy5,000$5.07-63.31view

Press Releases about ONTY :

    Quarterly/Annual Reports about ONTY:

    News about Onty:

    Articles On GuruFocus.com
    Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
    pro-longs life Jul 30 2011 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    cooldecency99 note on ONTY May 01 2010 
    creiter note on ONTY Jan 03 2010 

    More From Other Websites
    ONCOTHYREON INC. Financials Nov 14 2014
    Oncothyreon to Present at Stifel 2014 Healthcare Conference Nov 12 2014
    Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial... Nov 10 2014
    Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial... Nov 10 2014
    10-Q for Oncothyreon, Inc. Nov 08 2014
    Oncothyreon posts 3Q loss Nov 06 2014
    Oncothyreon posts 3Q loss Nov 06 2014
    ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
    Oncothyreon Reports Third Quarter 2014 Financial Results Nov 06 2014
    Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call Oct 30 2014
    Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call Oct 30 2014
    ONCOTHYREON INC. Files SEC form 8-K/A, Financial Statements and Exhibits Oct 22 2014
    UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside Oct 21 2014
    Coverage initiated on Oncothyreon by H.C. Wainwright Oct 21 2014
    Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% Oct 06 2014
    ONCOTHYREON INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year Sep 23 2014
    ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Sep 18 2014
    Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock Sep 18 2014
    Oncothyreon Announces Proposed Public Offerings Sep 17 2014
    Will Oncothyreon (ONTY) Crush Estimates at Its Next Earnings Report? Sep 16 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK